Immune system secrets may improve breast cancer therapy

NCT ID NCT04614194

Recruiting now Knowledge-focused Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand how the immune system reacts to a common breast cancer treatment combination of letrozole and abemaciclib. Researchers will collect tumor and blood samples from 60 postmenopausal women with hormone receptor-positive breast cancer before and after two weeks of treatment. The goal is to see if immune cell changes can predict how well the cancer responds, which could help personalize future therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: letrozole and abemaciclib
What this could lead to: If successful, this could reveal how the immune system helps fight breast cancer, potentially guiding better treatment combinations in the future.
What could go wrong: This is a small, early-phase study focused on understanding immune changes, not on proving a new treatment works. Results may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Parkland Hospital
NOT_YET_RECRUITING

Dallas, Texas, 75039, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.